Navigation Links
In Combination With FOLFOX4, the Effect of Erbitux and Avastin On Survival Rates Will Drive Prescription Decisions in the Treatment of Stage III Colon Cancer
Date:2/20/2008

Following its Approval, Erbitux Will Earn Gold-Standard Status in 2011,

According to a New Report from Decision Resources

WALTHAM, Mass., Feb. 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug's effect on overall survival is the attribute that most influences oncologists' prescribing decisions in the treatment of stage III colon cancer. Clinical data and expert opinion shows that Bristol-Myers Squibb/ImClone Systems/Merck KGaA's Erbitux and Roche/Genentech/Chugai's Avastin have advantages in this attribute when used in combination with sales-leading FOLFOX4 treatment. FOLFOX4 is comprised of oxaliplatin (Sanofi-Aventis's Eloxatin/Eloxatine, Yakult's Elplat), 5- fluorouracil and leucovorin.

The new report entitled Colon Cancer (Stage III): Therapies Must Increase Survival over FOLFOX to Reach Blockbuster Status finds that surveyed oncologists indicate that a therapy which improves disease-free survival over FOLFOX4 at three years would earn a 60% patient share and achieve blockbuster status. The report forecasts that Avastin, in combination with FOLFOX4, will earn a 22% patient share in the U.S. stage III colon cancer market in 2016. Additionally, owing to its efficacy, safety and tolerability, Erbitux in combination with FOLFOX4 will earn gold-standard status for stage III colon cancer in 2011, following its approval for the indication in 2010 in the U.S. and Europe.

"When using both drugs in combination with FOLFOX4, experts gave Erbitux a slightly higher score over Avastin in safety and tolerability," said Marcus Hoyle, analyst at Decision Resources. "Oncologists indicated that the cardiovascular toxicity associated with VEGF inhibitors, such as Avastin, has a more negative impact on their prescribing decisions than the tissue disorders associated with EGFR inhibitors, such as Erbitux."

About the Report

Colon Cancer (Stage III): Therapies Must Increase Survival over FOLFOX to Reach Blockbuster Status is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial endpoints to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price- per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Combination of Thyroid Medicines Not Necessary
2. Combination therapy improves survival for certain prostate cancer patients
3. Enlarged Prostate Treatment Study Shows Combination of AVODART(R) and Tamsulosin Provides Greater Benefit Than Either Medication Alone
4. Drug combination shrinks breast cancer metastases in brain
5. Xeloda(R), Taxotere(R) and Herceptin(R) Combination Study Suggests Clinical Benefit in Invasive Breast Cancer with Shortened Treatment Cycle
6. 3-drug combination extremely promising as first-line therapy for multiple myeloma
7. Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting
8. ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity
9. Drug combination effective against multiple myeloma, researchers show
10. HIV drug resistance risk in mothers reduced by combination of common drugs
11. Quality Control: Nissan Quest to Feature micronAir(R) Combination Cabin Air Filters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are encouraged ... in mind, SIGVARIS has created a new line of anti-embolism stockings to help ... provide the benefits of graduated compression when transitioning from recovery to early rehabilitation. ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Dan ... headquartered in Jefferson County, is announcing the launch of a charity drive to ... number of homeless women and children in Birmingham has grown steadily since the ...
(Date:12/8/2016)... ... December 08, 2016 , ... Bill ... and business owners in and around central Kansas, is joining the Youth Horizons ... in the region. , Headquartered in Wichita, Youth Horizons works to empower area ...
(Date:12/7/2016)... York, NY (PRWEB) , ... December 07, 2016 ... ... amounts of the drug in their bodies, a researcher at the Icahn School ... journal Pediatric Research. , The study found that when young children are exposed ...
(Date:12/7/2016)... Atlanta, GA (PRWEB) , ... December 07, 2016 , ... ... en route to respond to an emergency medical call when he lost control of ... injuries. After being extricated from his vehicle, he was transported to Atlanta Medical Center, ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Research and Markets has announced the addition of ... their offering. ... The report provides separate comprehensive analytics for the ... Rest of World. Annual estimates and forecasts are provided ... provided for these markets. Market data and analytics are derived from primary ...
(Date:12/7/2016)... , Dec. 7, 2016 "Lantus (Insulin Glargine) Biosimilar Clinical ... on 37 biosimilar version of Lantus drug in clinical pipeline. Currently 5 ... , Japan , Kenya , ... Germany , China , Slovakia ... 1 & 2 diabetes mellitus. The patent on Lantus expired in 2014. ...
(Date:12/7/2016)... YORK , Dec. 7, 2016 Global ... This report on the global hospital linen supply and ... of this market on a global and regional level. ... forecast for the period between 2015 and 2024 based ... the dynamics of the market along with their impact ...
Breaking Medicine Technology: